ExonHit Therapeutics, Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease

20 December 2007 - ExonHit Therapeutics, a drug and diagnostic discovery company, announced today that it has obtained a regulatory approval to initiate a Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease. EHT 0202 is a compound, with a novel mechanism of action, which has shown benefits on memory and neuronal loss... ExonHit's Press Release -

AstraZeneca and Banner Alzheimer's Institute, collaboration to evaluate new tool targeting Alzheimer's disease

December 19, 2007 — The Banner Alzheimer’s Institute and AstraZeneca (NYSE:AZN) announced that they will collaborate to help advance understanding of Alzheimer’s disease and increase knowledge of potential new avenues for treatment through the use of cutting-edge brain imaging methods. The new alliance will focus on the evaluation and further development of a radioligand discovered by AstraZeneca. This radioligand is a molecule that binds to amyloid plaque — protein deposits in the brain that are a hallmark of Alzheimer’s disease — and allows the plaque to be measured in real time using a positron emission tomography (PET) scan... The Banner Alzheimer’s Institute's Press Release -

GlaxoSmithKline, neuroscience pipeline with compound 742457 for Alzheimer’s disease

Thursday 13 December 2007 - ...742457 — A novel treatment to delay the symptoms of Alzheimer’s disease : Alzheimer’s disease is a devastating neurological condition, with significant consequences on the quality of life for sufferers and their care givers. GSK has a broad programme of research ongoing in Alzheimer’s disease, including 742457, a novel treatment that selectively targets the 5HT6 receptors concentrated within the brain. These receptors are associated with learning and memory... GSK's Press Release -

Samaritan, Favorable Caprospinol Data At Alzheimer's Drug Development Summit

November 27, 2007 - ...In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of Alzheimer's , but may also reverse plaque-related brain injuries associated with the disease. The rats tested with the company's proprietary Alzheimer's rat model took on features similar to the crippling signs of dementia seen in human patients suffering from Alzheimer's; by treating the rats with Caprospinol, the rat's brain cells regained complete memory... Samaritan's Press Release -

BioArctic Neuroscience and Eisai, Agreement with Novel Antibody Treatment for Alzheimer’s Disease

December 3rd 2007. The Swedish biopharmaceutical company BioArctic Neuroscience AB and the Japanese pharmaceutical company Eisai Co. Ltd., today announced that they have signed an exclusive licence agreement for BAN2401, a novel humanized monoclonal antibody, which is being developed as a next-generation treatment for Alzheimer’s disease... [PDF] BioArctic's Press Release -

EXONHIT , A PROTOTYPE TO DETECT ALZHEIMER'S DISEASE FROM BLOOD

November 8, 2007 - ExonHit Therapeutics, a drug and diagnostic discovery company, has completed a prototype of the first blood-based Alzheimer's disease test. The company expects to have this test certified and to provide it as a service in its GLP (Good Laboratory Practices) compliant laboratories to the pharmaceutical industry as early as 2009... ExonHit's Press Release - Communiqué de Presse ExonHit -

Anavex , drug candidate for treatment of Alzheimer's disease

Nov. 28 , 2007 - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce promising developments with ANAVEX 1-41, the company's lead drug candidate for Alzheimer's disease. In recent pre-clinical animal studies, ANAVEX 1-41 prevented oxidative stress, which damages and destroys cells and is believed to be a primary cause of Alzheimer's disease. ANAVEX 1-41 also prevented the expression of caspase-3, an enzyme that plays a key role in programmed cell death and in the loss of cells in the hippocampus, the part of the brain that regulates learning, emotion and memory... Anavex' Press release -

Affiris, European Patent for Alzheimer’s Vaccine

November 2007. Affiris GmbH has been granted a Europe-wide patent for key elements of its Alzheimer’s vaccine. As a result, the company has exclusive rights of use to the peptide sequences for an innovative approach to vaccine development. The tolerability of the first Affiris vaccine, AFFITOPE AD01, is currently being tested as part of a phase I clinical trial... [PDF] Affiris' Press Release -

Biogen Idec and Neurimmune Therapeutics, ALLIANCE TO DEVELOP TREATMENTS FOR ALZHEIMER’S DISEASE

November 20, 2007 - Biogen Idec (NASDAQ: BIIB) and Neurimmune Therapeutics AG today announced they have entered into an agreement for the worldwide development and commercialization of novel, fully human antibodies for the treatment of Alzheimer's disease (AD)...Neurimmune will conduct research to identify potential therapeutic antibodies using the company's Reverse Translational Medicine (RTM) platform. Biogen Idec will be responsible for the development and commercialization of all products... Biogen's Press Release - Neurimmune's Press Release -

EPIX Pharmaceuticals , Second Discovery Program in Collaboration with GlaxoSmithKline

Nov. 5, 2007-... In December 2006, EPIX and GSK announced a worldwide multi-target strategic collaboration to discover, develop and market novel medicines targeting four G-protein coupled receptors (GPCRs) for the treatment of a variety of diseases, including EPIX's novel 5-HT4 partial agonist program, PRX-03140, which is in early-stage clinical development for the treatment of Alzheimer's disease... EPIX 's Press Release -

Pipex Pharmaceuticals, Anti-Copper COPREXA Demonstrates 40% Reduction of Insoluble Amyloid Beta in Animal Models of Alzheimer’s Disease

November 5, 2007 -- Pipex Pharmaceuticals, Inc. (AMEX: PP) (“Pipex”), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced the presentation of preliminary results using its lead anti-copper drug candidate, COPREXA (oral tetrathiomolybdate), in the most commonly utilized transgenic pre-clinical murine model of Alzheimer’s Disease (AD) at the 2007 Society for Neuroscience annual meeting on November 4th in San Diego, CA... Pipex Pharmaceuticals' Press Release -

EnVivo Pharmaceuticals, Progress on Major Drug Program Focusing on Alzheimer’s Diseases

October 17, 2007 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, announced progress on several key programs for addressing Alzheimer’s*, Schizophrenia and Huntington’s diseases... The company believes that this lead compound represents one of the first highly potent, orally bio-available and brain-permeable HDAC inhibitors for neuro-degenerative diseases. HDAC inhibitors hold promise for treating the cognitive deficits of several diseases including Alzheimer’s disease... EnVivo's Press Release-

Memory Pharmaceuticals, Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease

Oct. 15 , 2007 - Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced top-line data from the multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MEM 1003, a neuronal L-type calcium channel modulator, in Alzheimer's disease.The trial enrolled 183 subjects with mild to moderate Alzheimer's disease at over 40 centers in the United States and included monotherapy subjects and subjects on stable doses of cholinesterase inhibitors. The trial failed to meet its primary endpoint, which was a twelve-week mean change in the Alzheimer's disease Assessment Scale* -- Cognitive subscale (ADAS-cog) score in the overall population. ... Memory Pharmaceuticals' Press Release-

Satoris and First Blood Test to Diagnose Alzheimer's Disease

October 15, 2007 - — A team of international researchers reported they have identified a group of cell-signaling proteins found in blood that serve as a unique “voiceprint” that can not only be used to diagnose Alzheimer’s disease*, but also classify and predict presymptomatic individuals who will eventually develop the memory-robbing disorder. The study describing the new test appears in this week’s online version of the scientific journal, Nature Medicine. “Our technology enables us to ‘listen’ to the chatter of cells communicating with each other and determine if there’s anything abnormal,” said Tony Wyss-Coray, Ph.D., a lead scientist in the study, and a co-founder of San Francisco-based Satoris Inc. ... Satoris ' Press Release-

AlzPosition, Alzheimer and Treatments blog

The aim of the Blog "AlzPosition" is to share information found in life sciences companies websites which could be interesting to follow pharmaceuticals, treatments, diagnostic tests, clinical trials about Alzheimer treatments.